Short-term Efficacy and Predictive Index of Anlotinib Hydrochloride Capsule on Advanced Non-small Cell Lung Cancer

WANG Wei; XIE Xiaoliang; YAN Didi

doi:10.3971/j.issn.1000-8578.2020.19.1282

Cancer Research on Prevention and Treatment > 2020 > 47(11): 851-855. > DOI: 10.3971/j.issn.1000-8578.2020.19.1282

WANG Wei, XIE Xiaoliang, YAN Didi. Short-term Efficacy and Predictive Index of Anlotinib Hydrochloride Capsule on Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(11): 851-855. DOI: 10.3971/j.issn.1000-8578.2020.19.1282

Citation:

PDF (3022 KB)

Short-term Efficacy and Predictive Index of Anlotinib Hydrochloride Capsule on Advanced Non-small Cell Lung Cancer

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

Funding:

Natural Science Foundation of He'nan Province 162300410291

He'nan Science and Technology Research Project 162102310153

He'nan Science and Technology Research Project 152102310180

He'nan Science and Technology Research Project 142102310330

More Information

Received Date: October 13, 2019
Revised Date: May 26, 2020
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To evaluate the short-term efficacy and predictive index of anlotinib hydrochloride capsule on advanced NSCLC patients.
Methods
We retrospectively reviewed the clinical characteristics of 83 patients with non-small cell lung cancer who had received the second-line chemotherapy. Kaplan-Meier method was used to calculate the rate of PFS. Log rank method was used for statistical test of survival curve. Cox regression model was used to analyze the influence of multiple factors on progress free survival (PFS). ROC curve was used analyze the prognostic value of multiple indicators.
Results
Among 83 patients with advanced NSCLC, there were 0 case of CR, 10 cases of PR, 56 cases of SD and 17 cases of PD. The side-effect could be controlled. The ORR and DCR were 12.0% and 79.5%, respectively. The mPFS was 4.43 months. In univariate analysis, the patients with ECOG score≥2, hypoalbuminemia, pleural effusion, elevated GGT and CYFRA21-1, decreased Pct and vascular tumor embolus had shorter PFS. Multivariable Cox regression analysis showed ECOG score, hypoalbuminemia, pleural effusion, CYFRA21-1 and vascular tumor embolus were independent prognostic factors.
Conclusion
For patients with non-small cell lung cancer progressing after the second-line treatment, the third-line treatment with anlotinib is safe and effective. Patients with ECOG score≥2, increased CYFRA21-1, hypoalbuminemia, pleural effusion and vascular tumor emboli have a poor prognosis. CYFRA21-1 has relatively high predictive value.
- Lung neoplasms,
- Predictive factor,
- Anlotinib hydrochloride capsule,
- Prognosis

FullText(HTML)

References (27)

References

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. doi: 10.3322/caac.21442
[2]	Hisakane K, Yoh K, Nakamura N, et al. Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer[J]. Medicine (Baltimore), 2017, 96(47): e8635. doi: 10.1097/MD.0000000000008635
[3]	Villano JL, Durbin EB, Normandeau C, et al. Incidence of brain metastasis at initial presentation of lung cancer[J]. Neuro Oncol, 2015, 17(1): 122-128. doi: 10.1093/neuonc/nou099
[4]	宋勇, 高健伟.精准医学时代的晚期非小细胞肺癌内科治疗进展[J].医学研究生学报, 2017, 30(11): 1121-1127. http://www.cnki.com.cn/Article/CJFDTotal-JLYB201711001.htm Song Y, Gao JW. Medical treatment of non-small cell lung cancer: An update[J]. Yi Xue Yan Jiu Sheng Xue Bao, 2017, 30(11): 1121-1127. http://www.cnki.com.cn/Article/CJFDTotal-JLYB201711001.htm
[5]	Han BH, Li K, Zhao YZ, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase Ⅱ trial (ALTER0302)[J]. Br J Cancer, 2018, 118(5): 654-661. doi: 10.1038/bjc.2017.478
[6]	La Monica S, Cretella D, Bonelli M, et al. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines[J]. J Exp Clin Cancer Res, 2017, 36(1): 174. doi: 10.1186/s13046-017-0653-7
[7]	Yang MM, Xu XX, Cai J, et al. NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors[J]. Int J Cancer, 2016, 139(1): 171-176. http://smartsearch.nstl.gov.cn/paper_detail.html?id=409a7936c8779d4206ab867233c27488
[8]	Toffalorio F, Santarpia M, Radice D, et al. 5'-nucleotidase cN-Ⅱ emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lungbining inhibitors of ALK cancer[J]. Oncotarget, 2018, 9(23): 16437-16450. doi: 10.18632/oncotarget.24505
[9]	Shaw AT. Combining Inhibitors of ALK and ROS1 With Other Agents for the Treatment of Non-Small Cell Lung Cancer[J]. Clin Adv Hematol Oncol, 2015, 13(5): 282-284. http://smartsearch.nstl.gov.cn/paper_detail.html?id=1440797f5b8589a9ef820898a7b6b883
[10]	Jayson GC, Kerbel R, Ellis LM, et al. Antiangiogenic therapy in oncology: current status and future directions[J]. Lancet, 2016, 388(10043): 518-529. doi: 10.1016/S0140-6736(15)01088-0
[11]	Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel VEGFR2 inhibitors[J]. Ann Transl Med, 2014, 2(12): 123. http://old.med.wanfangdata.com.cn/viewHTMLEn/PeriodicalPaper_PM25568876.aspx
[12]	Song Z, Yu X, Lou G, et al. Salvage treatment with apatinib for advanced non-small-cell lung cancer[J]. Onco Targets Ther, 2017, 10: 1821-1825. doi: 10.2147/OTT.S113435
[13]	Xu J, Liu X, Yang S, et al. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer[J]. Asia Pac J Clin Oncol, 2018, 14(3): 264-269. doi: 10.1111/ajco.12834
[14]	Yang CX, Feng W, Wu D. Apatinib for advanced non small-cell lung cancer: A retrospective case series analysis[J]. J Cancer Res Ther, 2018, 14(1): 159-162. http://www.ncbi.nlm.nih.gov/pubmed/29516980
[15]	Costa DB, Shaw AT, Ou SH, et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases[J]. J Clin Oncol, 2015, 33(17): 1881-1888. doi: 10.1200/JCO.2014.59.0539
[16]	Horio Y, Mizuno T, Sakao Y, et al. Successful salvage surgery following multimodal therapy in a patient who harboured ALK-rearranged advanced lung adenocarcinoma with multiple organ metastases[J]. Respirol Case Rep, 2019, 7(7): e00451. doi: 10.1002/rcr2.451
[17]	Han B, Li K, Wang Q, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2018, 4(11): 1569-1575. doi: 10.1001/jamaoncol.2018.3039
[18]	Zhang D, Zhang CF, Huang JQ, et al. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage Ⅲ/Ⅳ non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study[J]. Thorac Cancer, 2018, 9(12): 1754-1762. doi: 10.1111/1759-7714.12898
[19]	Girard N, Jacoulet P, Gainet M, et al. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice[J]. J Thorac Oncol, 2009, 4(12): 1544-1549. doi: 10.1097/JTO.0b013e3181bbf223
[20]	宋娟, 刘丹, 李镭, 等.肺癌伴发胸腔积液的临床特征及生存特点[J].华西医学, 2018, 33(1): 36-40. Song J, Liu D, Li L, et al. Clinical features and survival of lung cancer with pleural effusions[J]. Huaxi Yi Xue, 2018, 33(1): 36-40.
[21]	Porcel JM, Gasol A, Bielsa S, et al. Clinical features and survival of lung cancer patients with pleural effusions[J]. Respirology, 2015, 20(4): 654-659. doi: 10.1111/resp.12496
[22]	洪萍, 刘爱英.四种肿瘤标志物联合检测在肺癌诊断、治疗检测及判断预后的价值[J].临床肺科杂志, 2012, 17(4): 677-679. http://www.cnki.com.cn/Article/CJFDTotal-LCFK201204049.htm Hong P, Liu AY. Value of serum CEA, CYFRA21-1, NSE and CA125 in lung cancer diagnosis, treatment and prognosis[J]. Lin Chuang Fei Ke Za Zhi, 2012, 17(4): 677-679. http://www.cnki.com.cn/Article/CJFDTotal-LCFK201204049.htm
[23]	卢畅, 申淑景, 毛玉焕, 等. CEA、CYFRA21-1、NSE水平与EGFR突变的晚期肺腺癌患者临床疗效的相关性[J].肿瘤防治研究, 2017, 44(7): 485-488. doi: 10.3971/j.issn.1000-8578.2017.16.1530 Lu C, Shen SJ, Mao YH, et al. Correlation of Tumor Markers with Clinical Efficacy of Advanced Lung Adenocarcinoma Patients with EGFR Mutation[J]. Zhong Liu Fang Zhi Yan Jiu, 2017, 44(7): 485-488. doi: 10.3971/j.issn.1000-8578.2017.16.1530
[24]	张奕加, 朱雄鹏, 刘德斌, 等.血液科血液肿瘤患者低白蛋白血症的原因及临床意义[J].中华内科杂志, 2001, 40(6): 409-410. Zhang YJ, Zhu XP, Liu DB, et al. The causes and clinical significance of hypoalbuminemia in hematologic tumor patients[J]. Zhonghua Nei Ke Za Zhi, 2001, 40(6): 409-410.
[25]	陈泓竹, 刘建明, 周芳, 等.内源性物质代谢对药物代谢处置的影响及机制研究[J].中国临床药理学与治疗学, 2019, 24(5): 580-588. http://www.cqvip.com/QK/85070X/20195/7002056226.html Chen HZ, Liu JM, Zhou F, et al. Effect and mechanism of endogenous metabolism on drug metabolism and disposition[J]. Zhongguo Lin Chuang Yao Li Xue Yu Zhi Liao Xue, 2019, 24(5): 580-588. http://www.cqvip.com/QK/85070X/20195/7002056226.html
[26]	Chen WH, Huang YL, Chao YK, et al. Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy[J]. Ann Surg Oncol, 2015, 22(1): 338-343. doi: 10.1245/s10434-014-3881-5
[27]	Mori D, Yamasaki F, Shibaki M, et al. Lateral peritumoral lymphatic vessel invasion can predict lymph node metastasis in esophageal squamous cell carcinoma[J]. Mod Pathol, 2007, 20(6): 694-700. doi: 10.1038/modpathol.3800786

[1]	HE Jiawei, CAO Longnyu, TANG Mengyuan, CUI Hongquan. Causal Relationships Between Immune Cells and Risk of Gastric Cancer: A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 172-176. DOI: 10.3971/j.issn.1000-8578.2025.24.0438
[2]	WU Tong, GAO Fei, TENG Fei, ZHANG Qiaoli. Genetic Determinants of Immune Cells and Hepatocellular Carcinoma Risk: A Bioinformatics and Bidirectional Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2025, 52(1): 42-51. DOI: 10.3971/j.issn.1000-8578.2025.24.0562
[3]	YUAN Chendong, SHU Xufeng, WANG Xiaoqiang, JIE Zhigang. Relationship Between High-Density Lipoprotein Cholesterol and Colorectal Cancer—A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 847-851. DOI: 10.3971/j.issn.1000-8578.2024.24.0153
[4]	GONG Wanli, HOU Yaqi, WANG Yue, LI Yuan, QI Rongxuan, YU Qi, ZHANG Juan. Immune Cell-Mediated Effect of Lipid Profile on Colorectal Cancer: A Two-Step, Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 831-839. DOI: 10.3971/j.issn.1000-8578.2024.24.0284
[5]	LIU Jingting, ZHOU Yawei, KONG Lingguo, WANG Qiandan, SU Tianxiong, PEI Jianying, LI Yan. Causal Association Between Immune Cells and Cervical Cancer: A Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(9): 772-778. DOI: 10.3971/j.issn.1000-8578.2024.24.0037
[6]	WANG Yuanhang, SONG Zhiyuan, LU Ping, ZHANG Min. Analysis of Association Between Immune Cells and Breast Cancer Based on Two-sample Mendelian Randomization Method[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 348-352. DOI: 10.3971/j.issn.1000-8578.2024.23.1125
[7]	LIU Longjiao, YAO Yufeng. Circulating Inflammatory Proteins in Relation to Risk of Breast Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 342-347. DOI: 10.3971/j.issn.1000-8578.2024.23.1344
[8]	WEI Wei, LIU Ming, XU Jianguo, GAO Ya, SHEN Caiyi, TIAN Jinhui. Causal Relationship Between Acromegaly and Colon Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1209-1213. DOI: 10.3971/j.issn.1000-8578.2023.23.0507
[9]	WANG Mengyuan, XU Hengmin, WANG Jingxuan, PAN Kaifeng, LI Wenqing. Mendelian Randomization Analysis of Research on Risk Factors for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(5): 470-476. DOI: 10.3971/j.issn.1000-8578.2023.22.1411
[10]	Xin-ying ZHOU, Hu ZHANG, Hai-yan DAI. Mendelian randomization analysis of the correlation between interleukin and the risk of gynecological tumors[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.20240994

Cited By

Cited by

Periodical cited type(13)

1.	吴杨，隋雨桐，李斌鹏，韩路拓，姜家康. 激酶/转录因子信号通路调控肺癌机制及中医药干预的研究进展. 世界中医药. 2025(01): 142-147+154 .
2.	曹家瑞，冯博，马纯政，陈伟霞，喻江凡，曹莎莎，张振予，欧阳文慧. 中医药调控JAK/STAT信号通路干预肺癌的机制研究进展. 中国实验方剂学杂志. 2025(09): 265-276 .
3.	梁帅，尹怡，刘湘花，汪保英，骆文龙，龙云凯，任振杰，王祥麒. 升降理肺消瘤汤对Lewis肺癌小鼠免疫炎性反应和JAK2/STAT3信号通路的影响. 辽宁中医药大学学报. 2024(04): 27-32 .
4.	张彩蝶，靳艳，张德德. 润肺益肾饮对肺癌荷瘤大鼠的抑瘤作用和肿瘤免疫微环境的影响. 天津医药. 2024(04): 362-366 .
5.	孙喜，王召路，贾谨睿，王梦洋，孙润卓，王鹏，史新娥. 虫草素及其在生猪养殖中的应用. 畜牧兽医杂志. 2024(04): 1-7 .
6.	兰春燕，杨小兰，贺雪峰，赵丹，杨海燕. 甘草苷对胃癌荷瘤小鼠免疫功能的调节作用及机制研究. 中国药房. 2024(15): 1862-1867 .
7.	张景淇，郭静，陈娅欣，蒲玥衡，向俊杰. 中药调控肺癌相关信号通路研究进展. 中国实验方剂学杂志. 2024(19): 233-244 .
8.	张孟恩，韩睿，徐超，庞训胜，王世琴. 地顶孢霉培养物在反刍动物生产中的应用研究进展. 中国畜牧杂志. 2024(12): 70-74 .
9.	高铭，丁美灵，雷紫琴，胡靖文，栾飞，曾南. 荆防败毒散及其中成药制剂研究进展. 中药药理与临床. 2023(05): 112-118 .
10.	朱亚兰，吕世文，曾晨欣，徐媛青. 苍术素对非小细胞肺癌细胞上皮间质转化的影响及机制研究. 浙江医学. 2023(10): 1013-1018 .
11.	陈才伟，陈家亮，李华娟，方芳，文方玲. 虫草素调节MAPK/AP-1信号通路对慢性阻塞性肺疾病大鼠肺组织损伤的影响. 临床肺科杂志. 2023(11): 1656-1661 .
12.	李翔子，王西双，范建伟，杨田野，王丽娟，孙颖，姚景春. 荆防合剂通过抑制JAK2-STAT3信号通路调节荨麻疹小鼠脾脏T淋巴细胞亚群的平衡. 中国中药杂志. 2022(20): 5473-5480 .
13.	沈栩岚，黄凌霞. 虫草素的抗癌机理. 蚕桑通报. 2022(02): 33-34 .

Other cited types(4)

Get Citation

PDF

XML

Article views (1629) PDF downloads (671) Cited by(17)

Turn off MathJax

Article Contents

Abstract

References

Short-term Efficacy and Predictive Index of Anlotinib Hydrochloride Capsule on Advanced Non-small Cell Lung Cancer